Pharma News

In children in the US and UK, a sudden increase in the number of cases of severe acute hepatitis of unknown causes (SAHUC) and pediatric acute liver failure was reported between October 2021 and Ma...

British scientists have found a potential treatment for people living with hemophilia B.

VBL Therapeutics’ investigational drug ofra-vec (ofranergene obadenovec; VB-111) failed to show promise in a late-stage study for treatment of platinum-resistant ovarian cancer. ...

Japan’s Health, Labor and Welfare Ministry panel postponed a decision to approve Shionogi’s oral COVID-19 antiviral drug Xocova.

As many Korean pharmaceutical manufacturers are currently attempting to develop new drugs for idiopathic pulmonary fibrosis, Daewoong Pharmaceutical Co., Ltd.'s new medication DWN12088 has been fas...

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved QSYMIA (phentermine and topiramate extended-release capsules) CIV for use in the treatment of obesity in adoles...

The FDA has expanded its approval of Incyte’s Opzelura (ruxolitinib) topical cream to include adult and pediatric patients 12 years and older with nonsegmental vitiligo, a chronic autoimmune dis...

The FDA has approved Azurity Pharmaceuticals’ Zonisade (zonisamide oral suspension) as an adjunctive therapy for the treatment of partial seizures in epilepsy patients aged 16 years and older. ...

Currently, there is no cure for amyotrophic lateral sclerosis (ALS). 

Polpharma Biologics has become the first company to file for approval in the EU of a biosimilar version of Biogen’s blockbuster multiple sclerosis therapy Tysabri. ...

Scientists at Cedars-Sinai Medical Center in Los Angeles are trying to find new ways to produce huge batches of a type of stem cell that can generate nearly any other type of cell in the body -- an...

The European Medicines Agency has accepted Byondis’ application for its investigational drug trastuzumab duocarmazine for treatment of patients with human epidermal growth factor receptor 2 (HER2...